医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZELTIQ® Aesthetics to Showcase CoolCurve+ Applicator at IMCAS Asia Hong Kong 2012

2012年10月04日 AM09:11
このエントリーをはてなブックマークに追加


 

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced Henry H. Chan, MD, PhD, FRCP, will perform a live demonstration of CoolCurve+, the newest addition to the applicator platform for the CoolSculpting® System, at the International Master Course on Aging Skin (IMCAS) Asia in Hong Kong on October 5, 2012. Developed for enhanced fit and tissue draw, the anatomically curved shape of the CoolCurve+ applicator allows physicians to treat a multitude of body shapes.

WHAT:

    Session 22 – Lasers, Lights, Energy-Based Devices
Live CoolSculpting Demonstration with CoolCurve+ Applicator
 

WHEN:

Friday, October 5, 10:10-10:30 a.m.
 

WHERE:

International Master Course on Aging Skin (IMCAS) Asia
InterContinental Hong Kong Hotel
18 Salisbury Road, Kowloon, Hong Kong SAR
Room 3
 

WHO:

Henry H. Chan, MD, PhD, FRCP

 

For more information about CoolCurve+ and CoolSculpting, visit ZELTIQ Aesthetics at Booth B08. Exhibition hours are as follows: Friday, October 5, 8:30 a.m. to 6 p.m.; Saturday, October 6, 8:30 a.m. to 2 p.m.

About ZELTIQ Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

CONTACT

Neo Derm for ZELTIQ
Colin Leung
+852 9303 0338
colin.leung@neoderm.com.hk

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates